← Back to Search
Ocular Delivery Of Nucleic Acids: Antisense Oligonucleotides, Aptamers And SiRNA.
E. Fattal, A. Bochot
Published 2006 · Biology, Medicine
Download PDFAnalyze on Scholarcy
Nucleic acids have gained a lot of interest for the treatment of ocular diseases. The first to enter in clinic has been Vitravene an antisense oligonucleotide for the treatment of cytomegalovirus (CMV) infection and more recently, research on aptamers have led to the marketing of anti-vascular endothelial growth factor (VEGF) inhibitor (Macugen) for the treatment of age-related macular degeneration (AMD). The siRNAs appear very promising as they are very potent inhibitors of protein expression. Despite their potential, nucleic acids therapeutic targets of nucleic acid-based drugs are mainly located in the posterior segment of the eye requiring invasive administration which can be harmful if repeated. Their intracellular penetration in some cases needs to be enhanced. This is the reason why adequate delivery systems were designed either to insure cellular penetration, protection against degradation or to allow long-term delivery. A combination of both effects was also developed for an implantable system. In conclusion, the intraocular administration of nucleic acids offers interesting perspectives for the treatment of ocular diseases.
This paper references
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Eugene W. M. Ng (2006)
Nucleic acid therapeutics: state of the art and future prospects.
A. Gewirtz (1998)
Inhibition of Ocular Angiogenesis by Diced Small Interfering RNAs (siRNAs) Specific to Vascular Endothelial Growth Factor (VEGF)
M. Murata (2006)
Iontophoresis: from the lab to the bed side.
M. Halhal (2004)
Antisense technologies. Improvement through novel chemical modifications.
J. Kurreck (2003)
Human scleral permeability. Effects of age, cryotherapy, transscleral diode laser, and surgical thinning.
T. Olsen (1995)
Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans.
R. Ketting (2001)
Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres.
K. Carrasquillo (2003)
Oligonucleotide-Polyethylenimine Complexes Targeting Retinal Cells: Structural Analysis and Application to Anti-TGFβ-2 Therapy
A. L. Gomes dos Santos (2006)
INTRAVITREAL INJECTION OF VASCULAR ENDOTHELIAL GROWTH FACTOR SMALL INTERFERING RNA INHIBITS GROWTH AND LEAKAGE IN A NONHUMAN PRIMATE, LASER-INDUCED MODEL OF CHOROIDAL NEOVASCULARIZATION
M. Tolentino (2004)
Gene transfer with lipospermines and polyethylenimines.
Morpholino antisense oligomers: design, preparation, and properties.
J. Summerton (1997)
Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring.
M. Shah (1995)
Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera.
K. M. Hämäläinen (1997)
Eleven loci encoding trans-acting factors are required for transient complementation of human cytomegalovirus oriLyt-dependent DNA replication.
G. Pari (1993)
Expression of human cytomegalovirus UL36 and UL37 genes is required for viral DNA replication.
J. A. Smith (1995)
Cell delivery and mechanisms of action of antisense oligonucleotides.
J. P. Leonetti (1993)
Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region.
R. Azad (1993)
Antiviral activity of an oligo(nucleoside methylphosphonate) that targets HSV-1 immediate-early pre-mRNA 4,5 is augmented by cotreatment with replication-defective adenovirus.
M. Kulka (1995)
Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide.
A. Arnedo (2004)
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
Emmett T Cunningham (2005)
Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA.
K. P. Anderson (1996)
Phosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system.
N. Ogata (1999)
Pharmacologic and Pharmacokinetic Assessment of Anti-TGFβ2 Aptamers in Rabbit Plasma and Aqueous Humor
Thomas G. McCauley (2005)
Neural retina limits the nonviral gene transfer to retinal pigment epithelium in an in vitro bovine eye model
L. Pitkänen (2008)
Characterization of oligonucleotide transport into living cells.
S. Loke (1989)
Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms.
A. Bochot (1998)
Synergistic antiviral activities of oligonucleoside methylphosphonates complementary to herpes simplex virus type 1 immediate-early mRNAs 4, 5, and 1.
M. Kulka (1994)
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Eugene W. M. Ng (2005)
RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW
R. D. Jager (2004)
Particle Formation by a Conserved Domain of the Herpes Simplex Virus Protein VP22 Facilitating Protein and Nucleic Acid Delivery* 210
N. Normand (2001)
Potent antiviral activity of an antisense oligonucleotide complementary to the intron-exon boundary of human cytomegalovirus genes UL36 and UL37.
G. Pari (1995)
Treatments for choroidal and retinal neovascularization: a focus on oligonucleotide therapy and delivery for the regulation of gene function
R. J. Marano (2005)
Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4.
M. Kulka (1989)
2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)
J. Ruckman (1998)
Biodegradable microparticles for the controlled delivery of oligonucleotides.
G. De Rosa (2002)
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.
E. Pierce (1995)
Role of transforming growth factor beta in conjunctival scarring.
M. Cordeiro (2003)
Delivery of antisense oligonucleotide to the cornea by iontophoresis.
M. Berdugo (2003)
Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
H. Kourlas (2006)
Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: physicochemical and transfection studies.
M. Ruponen (1999)
In vivo use of oligonucleotides to inhibit choroidal neovascularisation in the eye
K. Garrett (2001)
Biodegradation and tissue reaction to intravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres.
G. G. Giordano (1995)
Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922)
G. Mulamba (1998)
Pharmacokinetics and Biodistribution of Novel Aptamer Compositions
Judith M. Healy (2004)
Extracellular Glycosaminoglycans Modify Cellular Trafficking of Lipoplexes and Polyplexes*
M. Ruponen (2001)
A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes.
G. De Rosa (2003)
Direct in vitro selection of a 2'-O-methyl aptamer to VEGF.
P. Burmeister (2005)
Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity
R. J. Marano (2005)
Improved anti-herpes simplex virus type 1 activity of a phosphodiester antisense oligonucleotide containing a 3'-terminal hairpin-like structure.
B. Poddevin (1994)
Optimization of non-viral gene transfer to human primary retinal pigment epithelial cells.
K. Abul-Hassan (2000)
Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis.
B. Kim (2004)
VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
N. Normand (2005)
A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonucleotides.
I. Jääskeläinen (2000)
Vitreous Is a Barrier in Nonviral Gene Transfer by Cationic Lipids and Polymers
L. Pitkänen (2004)
Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugs.
J. M. Irache (2005)
Extracellular and intracellular barriers in non-viral gene delivery.
M. Ruponen (2003)
Novel antisense oligonucleotides targeting TGF-β inhibit in vivo scarring and improve surgical outcome
M. Cordeiro (2003)
Aptamers against extracellular targets for in vivo applications.
C. Pestourie (2005)
Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization
R. Danis (2003)
Inhibition of herpes simplex virus replication by antisense oligo-2'-O-methylribonucleoside methylphosphonates.
J. Kean (1995)
Antisense oligonucleotides as therapeutic agents--is the bullet really magical?
C. Stein (1993)
Site-Specific Administration of Antisense Oligonucleotides using Biodegradable Polymer Microspheres Provides Sustained Delivery and Improved Subcellular Biodistribution in the Neostriatum of the Rat Brain
A. Khan (2000)
Supramolecular structures from dendrons and dendrimers.
K. Al-Jamal (2005)
Phosphorothioate antisense oligodeoxynucleotides: questions of specificity.
C. Stein (1996)
Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes.
G. De Rosa (2002)
Transforming growth factor‐β1 expression in cultured corneal fibroblasts in response to injury
Q. H. Song (2000)
Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
M. E. Myles (2005)
Gene Delivery and Expression in Human Retinal Pigment Epithelial Cells: Effects of Synthetic Carriers, Serum, Extracellular Matrix and Viral Promoters
A. Urtti (2000)
Nucleic-acid therapeutics: basic principles and recent applications
J. Opalinska (2002)
Evaluation of retinal toxicity and efficacy of anti-cytomegalovirus and anti-herpes simplex virus antiviral phosphorothioate oligonucleotides ISIS 2922 and ISIS 4015.
M. Flores-Aguilar (1997)
Cytoplasmic RNA modulators of an inside-out signal-transduction cascade.
M. Blind (1999)
Determination of oligonucleotide ISIS 2922 in nanoparticulate delivery systems by capillary zone electrophoresis.
A. Arnedo (2000)
Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles.
Jean-Louis Bourges (2003)
Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides
S. Roy (1999)
Antiviral effect of oligo(nucleoside methylphosphonates) complementary to the herpes simplex virus type 1 immediate early mRNAs 4 and 5.
M. Kulka (1993)
Vitreous: a barrier to nonviral ocular gene therapy.
L. Peeters (2005)
Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery.
A. L. Gomes dos Santos (2006)
Long-term release and improved intracellular penetration of oligonucleotide-polyethylenimine complexes entrapped in biodegradable microspheres.
G. De Rosa (2003)
Keratocyte migration and peptide growth factors: the effect of PDGF, bFGF, EGF, IGF-I, aFGF and TGF-beta on human keratocyte migration in a collagen gel.
J. Andresen (1997)
Antisense basic fibroblast growth factor oligonucleotide reduced adhesion of retinal pigment epithelial cells to extracellular matrix molecules and their proliferation.
S. H. Rho (2001)
Down-regulation of NOSII gene expression by iontophoresis of anti-sense oligonucleotide in endotoxin-induced uveitis.
M. Voigt (2002)
Antisense and antigene properties of peptide nucleic acids.
J. Hanvey (1992)
Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy
A. P. Adamis (1994)
PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION
D. Martín (2002)
Preclinical Evaluation of a Phosphorothioate Oligonucleotide in the Retina of Rhesus Monkey
W. Shen (2002)
Molecular therapy in ocular wound healing
M. Cordeiro (1999)
Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1.
A. Peyman (1995)
Oligonucleotide N3'-->P5' phosphoramidates.
S. Gryaznov (1995)
Intravitreal delivery of oligonucleotides by sterically stabilized liposomes.
A. Bochot (2002)
Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.
D. Guyer (2003)
Gene transfer into eukaryotic cells using activated polyamidoamine dendrimers.
Jörg Dennig (2002)
Microspheres of biodegradable polymers as a drug-delivery system in the vitreous.
T. Moritera (1991)
Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides.
N. Wimmer (2002)
Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys
D. W. Drolet (2004)
Scleral permeability of a small, single-stranded oligonucleotide.
R. Shuler (2004)
Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs.
R. Azad (1995)
Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide.
R. J. Marano (2004)
Vascular endothelial growth factor: basic science and clinical progress.
N. Ferrara (2004)
Nanoparticles for gene delivery to retinal pigment epithelial cells.
R. Bejjani (2005)
Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.
G. Robinson (1996)
Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by antisense oligonucleotides.
B. Detrick (2001)
Diffusion of high molecular weight compounds through sclera.
J. Ambati (2000)
Aptamers: an emerging class of therapeutics.
S. Nimjee (2005)
Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
S. Henry (2001)
Comparison of two methods of encapsulation of an oligonucleotide into poly(D,L-lactic acid) particles.
F. Delié (2001)
Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor.
A. Kvanta (1996)
Oligonucleotide N3'-->P5' phosphoramidates as antisense agents.
S. Gryaznov (1996)
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine.
O. Boussif (1995)
Retinal pigment epithelial tear following intravitreal pegaptanib sodium.
M. S. Dhalla (2006)
Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection.
S. Hariprasad (2006)
Transscleral delivery of bioactive protein to the choroid and retina.
J. Ambati (2000)
Structural modifications of antisense oligonucleotides.
E. Urban (2003)
Pegaptanib for neovascular age-related macular degeneration.
E. Gragoudas (2004)
The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides.
Rosel Kretschmer-Kazemi Far (2003)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
Sayda M. Elbashir (2001)
Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation.
C. Hecquet (2002)
A gamma scintigraphic evaluation of the precorneal residence of liposomal formulations in the rabbit
P. Fitzgerald (1987)
[Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication].
M. Larsen (2005)
Topical treatment with antisense oligonucleotides targeting tumor necrosis factor-alpha in herpetic stromal keratitis.
S. Wasmuth (2003)
Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery
A. Bochot (2000)
Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model.
S. Reich (2003)
RNA interference targeting transforming growth factor-β type II receptor suppresses ocular inflammation and fibrosis
H. Nakamura (2004)
Aptamers—basic research, drug development, and clinical applications
D. Proske (2005)
Morpholino antisense oligomers: the case for an RNase H-independent structural type.
J. Summerton (1999)
Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
S. Agrawal (1999)
Phosphorothioate oligodeoxynucleotides inhibit basic fibroblast growth factor-induced angiogenesis in vitro and in vivo.
I. Kitajima (1999)
Endogenous and Exogenous Fibroblast Growth Factor 2 Support Survival of Chick Retinal Neurons by Control of Neuronal Neuronal bcl‐xL and bcl‐2 Expression Through a Fibroblast Berowth Factor Receptor 1‐ and Erk‐Dependent Pathway
L. Désiré (2000)
Use of Synthetic Dendrimer Peptide’s to Mediate the Delivery of a Sense Oligonucleotide
R. J. Marano (2003)
Induction of gene into the rabbit eye by iontophoresis: preliminary report.
T. Asahara (2001)
Micro- and nanoparticulates.
A. Moshfeghi (2005)
VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice.
D. Zavaglia (2003)
Transcriptional gene silencing in plants: targets, inducers and regulators.
H. Vaucheret (2001)
Requirements for delivery of active antisense oligonucleotides into cells with lipid carriers.
I. Jääskeläinen (2004)
This paper is referenced by
Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations
B. Short (2008)
Drug delivery systems for the eye
Victoria R Kearns (2009)
LIPID-BASED NANO AND MICROTECHNOLOGIES FOR INTRAOCULAR AND LUNG DELIVERY OF POORLY STABLE AND/OR POORLY ABSORBED ACTIVE DRUGS
E. Fattal (2008)
Composition d'iontophorèse comprenant un complexe arnsi-polycation
Kazuaki Kajimoto (2009)
Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye.
K. Hironaka (2009)
Liposomal siRNA nanocarriers for cancer therapy.
B. Ozpolat (2014)
Effects of CD25siRNA gene transfer on high-risk rat corneal graft rejection
Q. Qin (2015)
Splicing-correcting therapeutic approaches for retinal dystrophies: where endogenous gene regulation and specificity matter.
Niccolò Bacchi (2014)
New Techniques for Drug Delivery to the Posterior Eye Segment
E. Eljarrat-Binstock (2009)
Polymers in the co-delivery of siRNA and anticancer drugs to treat multidrug-resistant tumors
Can Sarisozen (2016)
Current Advances in Self-Assembly RNAi Nanoparticles
Ka-To Shum (2013)
Cancer, Drug Targeting and Targeted Therapies
Mumin Alper Erdoganc (2019)
Nanoengineered strategies for siRNA delivery: from target assessment to cancer therapeutic efficacy
D. Mishra (2016)
RNAi-based nanomedicines for targeted personalized therapy.
Ala Daka (2012)
Stimulation of ribosomal frameshifting by antisense LNA
Chien-hung Yu (2010)
Drug delivery systems for the posterior segment of the eye – in vitro evaluation of light triggered and pH-sensitive liposomes with gold nanoparticles
Oona Kosma (2016)
Ocular drug delivery – a look towards nanobioadhesives
L. D. du Toit (2011)
Nanomedicine based approaches for the delivery of siRNA in cancer
B. Ozpolat (2010)
Interference: an alteRNAtive therapy following acute myocardial infarction.
M. Monaghan (2012)
Tubocapsanolide A Inhibits Transforming Growth Factor-β-activating Kinase 1 to Suppress NF-κB-induced CCR7*
M. Pan (2009)
Efficient delivery of NF-κB siRNA to human retinal pigment epithelial cells with hyperbranched cationic polysaccharide derivative-based nanoparticles
Z. Liu (2015)
Chemical modification: the key to clinical application of RNA interference?
D. Corey (2007)
Microdialysis in Ocular Drug Development
M. Patel (2013)
Reducible Polyethylenimine Nanoparticles for Efficient siRNA Delivery in Corneal Neovascularization Therapy.
H. Han (2016)
RNAi mechanisms and applications.
D. Kim (2008)
DRUG DEVELOPMENT IN CONTEMPORARY ONCOLOGY
Thomas F. Duchaine (2009)
Tissue Distribution, Metabolism, and Clearance
M. Dirin (2018)
Glutathione-responsive nano-transporter-mediated siRNA delivery: silencing the mRNA expression of Ras
C. Doss (2012)
Age-dependent disease expression determines remodeling of the retinal mosaic in carriers of RPGR exon ORF15 mutations.
William A Beltran (2009)
Microneedles for enhanced transdermal and intraocular drug delivery
K. Moffatt (2017)
Suprachoroidal drug delivery to the eye using hollow microneedles
Samikumar R. Patel (2011)
Nanocarriers of nanotechnology in retinal diseases.
A. Alhalafi (2014)See more